AU2008347400B2 - Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives - Google Patents
Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives Download PDFInfo
- Publication number
- AU2008347400B2 AU2008347400B2 AU2008347400A AU2008347400A AU2008347400B2 AU 2008347400 B2 AU2008347400 B2 AU 2008347400B2 AU 2008347400 A AU2008347400 A AU 2008347400A AU 2008347400 A AU2008347400 A AU 2008347400A AU 2008347400 B2 AU2008347400 B2 AU 2008347400B2
- Authority
- AU
- Australia
- Prior art keywords
- imiquimod
- treatment
- cells
- colorectal
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000011282 treatment Methods 0.000 title claims description 13
- 206010009944 Colon cancer Diseases 0.000 title abstract description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 title abstract description 8
- 230000002265 prevention Effects 0.000 title abstract description 8
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title description 7
- 201000010989 colorectal carcinoma Diseases 0.000 title description 3
- 208000019399 Colonic disease Diseases 0.000 title description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229960002751 imiquimod Drugs 0.000 claims abstract description 44
- 238000009098 adjuvant therapy Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 11
- 208000022131 polyp of large intestine Diseases 0.000 claims description 10
- 208000015768 polyposis Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 abstract description 8
- 241000565118 Cordylophora caspia Species 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 abstract description 4
- 229940124669 imidazoquinoline Drugs 0.000 abstract description 4
- 229940124622 immune-modulator drug Drugs 0.000 abstract description 3
- 230000000699 topical effect Effects 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 20
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 13
- ZXBCLVSLRUWISJ-UHFFFAOYSA-N 2-methyl-1-(2-methylpropyl)imidazo[4,5-c][1,5]naphthyridin-4-amine Chemical compound C1=CC=NC2=C3N(CC(C)C)C(C)=NC3=C(N)N=C21 ZXBCLVSLRUWISJ-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000014081 polyp of colon Diseases 0.000 description 7
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 7
- 229950010550 resiquimod Drugs 0.000 description 7
- 229950008380 sotirimod Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000009621 actinic keratosis Diseases 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 230000002113 chemopreventative effect Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- WSIZDLIFQIDDKA-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinolin-2-amine Chemical compound C1=CC=NC2=C(NC(N)=N3)C3=CC=C21 WSIZDLIFQIDDKA-UHFFFAOYSA-N 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000017819 hyperplastic polyp Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 201000011138 superficial basal cell carcinoma Diseases 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US645908P | 2008-01-15 | 2008-01-15 | |
| US61/006,459 | 2008-01-15 | ||
| PCT/EP2008/011088 WO2009089900A1 (en) | 2008-01-15 | 2008-12-23 | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008347400A1 AU2008347400A1 (en) | 2009-07-23 |
| AU2008347400B2 true AU2008347400B2 (en) | 2014-12-11 |
Family
ID=40419193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008347400A Ceased AU2008347400B2 (en) | 2008-01-15 | 2008-12-23 | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8008319B2 (enExample) |
| EP (1) | EP2237780A1 (enExample) |
| JP (1) | JP2011509956A (enExample) |
| CN (1) | CN101909624A (enExample) |
| AU (1) | AU2008347400B2 (enExample) |
| BR (1) | BRPI0822002A2 (enExample) |
| CA (1) | CA2708559C (enExample) |
| EA (1) | EA018579B1 (enExample) |
| GE (1) | GEP20125605B (enExample) |
| IL (1) | IL205819A (enExample) |
| MX (1) | MX2010007699A (enExample) |
| NZ (1) | NZ586161A (enExample) |
| UA (1) | UA101339C2 (enExample) |
| WO (1) | WO2009089900A1 (enExample) |
| ZA (1) | ZA201003906B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA020488B1 (ru) | 2009-10-22 | 2014-11-28 | Джилид Сайэнс, Инк. | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| SG11201605449YA (en) | 2014-01-10 | 2016-08-30 | Birdie Biopharmaceuticals Inc | Compounds and compositions for immunotherapy |
| EP4001311B1 (en) | 2014-07-09 | 2025-11-05 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1/pd-1 combinations for treating tumors |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| US11517567B2 (en) * | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2078547C1 (ru) * | 1995-11-28 | 1997-05-10 | Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ | Способ лечения полипоза желудка и двенадцатиперстной кишки |
| UA74852C2 (en) * | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| AU2002219472A1 (en) * | 2001-01-02 | 2002-07-16 | Elisabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
| US20060193789A1 (en) * | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
| BRPI0416801A (pt) * | 2003-11-21 | 2007-01-09 | Novartis Ag | derivados de 1h-imidazoquinolina como inibidores de proteìna sinase |
-
2008
- 2008-12-23 MX MX2010007699A patent/MX2010007699A/es active IP Right Grant
- 2008-12-23 JP JP2010542534A patent/JP2011509956A/ja active Pending
- 2008-12-23 EA EA201001164A patent/EA018579B1/ru not_active IP Right Cessation
- 2008-12-23 AU AU2008347400A patent/AU2008347400B2/en not_active Ceased
- 2008-12-23 UA UAA201006372A patent/UA101339C2/ru unknown
- 2008-12-23 CA CA2708559A patent/CA2708559C/en not_active Expired - Fee Related
- 2008-12-23 EP EP08871156A patent/EP2237780A1/en not_active Withdrawn
- 2008-12-23 NZ NZ586161A patent/NZ586161A/en unknown
- 2008-12-23 BR BRPI0822002A patent/BRPI0822002A2/pt not_active IP Right Cessation
- 2008-12-23 CN CN2008801223531A patent/CN101909624A/zh active Pending
- 2008-12-23 GE GEAP200811913A patent/GEP20125605B/en unknown
- 2008-12-23 WO PCT/EP2008/011088 patent/WO2009089900A1/en not_active Ceased
-
2009
- 2009-01-14 US US12/353,683 patent/US8008319B2/en not_active Expired - Fee Related
-
2010
- 2010-05-17 IL IL205819A patent/IL205819A/en not_active IP Right Cessation
- 2010-06-01 ZA ZA2010/03906A patent/ZA201003906B/en unknown
Non-Patent Citations (4)
| Title |
|---|
| DIAKOMANOLIS, E., ET AL, "Treatment of High-Grade Vaginal Intraepithelial Neoplasia with Imiquimod Cream". The New England Journal of Medicine, 2002, vol. 347, no. 5, page 374 * |
| FLESHNER, P.R., ET AL, "Practice Parameters for Anal Squamous Neoplasms". Diseases of the Colon & Rectum, 2008, vol. 51, no. 1, pages 2-9 * |
| LIPKA, E., ET AL, "Evaluation of Imiquimod and Analogues with Respect to their Oral Delivery Potential". Proceedings of the Controlled Release Society, 1997, no. 24, pages 337-338 * |
| SIDKY, Y.A., ET AL, "Inhibition of Murine Tumor Growth by an Interferon-inducing Imidazoquinolinamine". Cancer Research, 1992, vol. 52, pages 3528-3533 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20125605B (en) | 2012-08-10 |
| JP2011509956A (ja) | 2011-03-31 |
| AU2008347400A1 (en) | 2009-07-23 |
| EA201001164A1 (ru) | 2010-12-30 |
| IL205819A (en) | 2013-02-28 |
| UA101339C2 (ru) | 2013-03-25 |
| CN101909624A (zh) | 2010-12-08 |
| NZ586161A (en) | 2012-05-25 |
| ZA201003906B (en) | 2011-03-30 |
| BRPI0822002A2 (pt) | 2015-10-13 |
| US8008319B2 (en) | 2011-08-30 |
| MX2010007699A (es) | 2010-08-04 |
| US20090182005A1 (en) | 2009-07-16 |
| CA2708559A1 (en) | 2009-07-23 |
| CA2708559C (en) | 2015-10-06 |
| EP2237780A1 (en) | 2010-10-13 |
| EA018579B1 (ru) | 2013-09-30 |
| WO2009089900A1 (en) | 2009-07-23 |
| IL205819A0 (en) | 2010-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008347400B2 (en) | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives | |
| Du et al. | cGAS-STING signaling in cancer immunity and immunotherapy | |
| Carvalho et al. | Radiotherapy and immune response: the systemic effects of a local treatment | |
| Balkwill et al. | Cancer-related inflammation: common themes and therapeutic opportunities | |
| Zheng et al. | Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression | |
| Xia et al. | Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells | |
| Feng et al. | Effect of grape procyanidins on tumor angiogenesis in liver cancer xenograft models | |
| EP2512469B1 (en) | 3-(indolyl)-or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarzinoma | |
| Hodges et al. | CoQ10: could it have a role in cancer management? | |
| JP2021169474A (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| Korets et al. | Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer | |
| Xu et al. | Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice | |
| JP2018517759A (ja) | カルボプラチンを含む組成物及び用途 | |
| WO2006084197A2 (en) | Nitroxides for use in treating or preventing neoplastic disease | |
| Sun et al. | Dehydrocostus lactone alleviates irinotecan-induced intestinal mucositis by blocking TLR4/MD2 complex formation | |
| Zadeh et al. | Autophagy-related chemoradiotherapy sensitivity in non-small cell lung cancer (NSCLC) | |
| Yu et al. | Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer | |
| Guo et al. | Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4 | |
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| Xu et al. | Radiation-based immunogenic vaccine combined with a macrophage “checkpoint inhibitor” for boosting innate and adaptive immunity against metastatic colon cancers | |
| JP7285001B2 (ja) | サフラナール製剤による肝臓癌治療の方法 | |
| Gkoulioni et al. | The efficacy of imiquimod on dysplastic lesions of the oral mucosa: an experimental model | |
| CN112121052A (zh) | 丙烯酰基苯并氮杂*类化合物在制备防治血液肿瘤药物中的用途 | |
| Zhang et al. | 5-Fluorouracil induces apoptosis of colorectal cancer cells | |
| CN115282280A (zh) | TGF-β1信号抑制剂的新用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application | ||
| NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 23 DEC 2012 TO 23 JUL 2013 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED . |
|
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 23 JUL 2013 . |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |